All In Biotech

Drug Trial Radar · NCT07255664

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

A FIH, Phase I/IIa, Open-label Trial Assessing Safety, Tolerability, and Feasibility of Repeated Administrations of a Novel Autologous TIL-based Immunotherapy in Patients With Metastatic Colorectal or Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 13, 2025

Primary completion

Apr 2027

Study completion Apr 2029

Sponsor

Lead sponsor
CuraCell TX ABIndustry
Sponsor type
Industry
Collaborators
Zellwerk GmbH; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Krebsforschung Rhein-Main e.V.
First posted
Dec 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.

Conditions

  • Metastatic Colorectal Cancer
  • Prostate Cancer Metastatic
  • Prostate Cancer Locally Advanced

Interventions

  • CC-38Drug

    CC-38 drug product is an autologous ATIMP composed of in vitro expanded tumor-infiltrating T-lymphocytes.

  • PembrolizumabDrug

    A concomitant IMP is pembrolizumab

  • CyclophosphamidDrug

    Cyclophosphamid is used as a AxMP

  • Interleukin-2Drug

    Interleukin-2 is used as a AxMP.

  • UromitexanDrug

    Uromitexan is used as a AxMP.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of safety, tolerability, and feasibility of repeated administrations of the novel ATIMP, CC-38.Time frame: 42 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Krankenhaus Nordwest

    Frankfurt, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.